Neutral
GlobeNewsWire
1 month ago
RenovoRx Expands RenovoCath® Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center
MOUNTAIN VIEW, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies, today announced continued commercial momentum with a growing number of U.S. cancer centers now integrating the Company's RenovoCath patented FDA-cleared drug-delivery device into oncology treatment programs. The Company's TAMP ™ (Trans-Arterial Micro-Perfusion) therapy platform, enabled by the RenovoCath device, is designed to deliver chemotherapy near the tumor site, potentially enhancing therapeutic effectiveness and minimizing the systemic side effects commonly associated with traditional intravenous chemotherapy administration.
